Literature DB >> 16902161

Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community.

Yariv Gerber1, Joseph P McConnell, Allan S Jaffe, Susan A Weston, Jill M Killian, Véronique L Roger.   

Abstract

OBJECTIVE: We evaluated the role of lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory biomarker, in defining risk after myocardial infarction (MI). METHODS AND
RESULTS: Olmsted County, Minn, residents who experienced an MI meeting standardized criteria between 2003 and 2005 (n = 271) were prospectively identified and followed. Lp-PLA2 levels were measured at baseline and evaluated along with traditional risk indicators. Lp-PLA2 was modestly associated with total and low-density lipoprotein cholesterol, smoking, and age (inversely) but not with MI characteristics or severity, comorbidities, C-reactive protein, or the time from symptom onset to blood sampling. During the first year of follow-up, 42 deaths occurred. The survival estimates (95% confidence intervals [CI]) at 1 year were 92% (86% to 98%), 85% (78% to 93%), and 74% (65% to 84%) in the lowest, middle, and upper Lp-PLA2 tertiles, respectively (P = 0.007). After adjustment for age and sex, the hazard ratios for death in the middle and upper Lp-PLA2 tertiles were 2.20 (95% CI: 0.88 to 5.54) and 4.93 (95% CI: 2.10 to 11.60), compared with the lowest tertile, respectively (P(trend) < 0.001). Further adjustment for other risk indicators resulted in even stronger associations. Lp-PLA2 also contributed to risk discrimination as indicated by the increases in the area under the receiver operating characteristic curves obtained in each of the models examined (all P < or = 0.05).
CONCLUSIONS: Among community subjects presenting with MI, increased Lp-PLA2 levels measured early after MI are strongly and independently associated with mortality and provide incremental value in risk discrimination over traditional predictors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902161     DOI: 10.1161/01.ATV.0000240406.89440.0c

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  28 in total

Review 1.  Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2.

Authors:  Robert S Rosenson; Diana M Stafforini
Journal:  J Lipid Res       Date:  2012-06-04       Impact factor: 5.922

2.  Lipoprotein-associated phospholipase A2 and cardiovascular disease risk in HIV infection.

Authors:  A Ross Eckard; C T Longenecker; Y Jiang; S M Debanne; D Labbato; N Storer; G A McComsey
Journal:  HIV Med       Date:  2014-03-20       Impact factor: 3.180

Review 3.  Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

Authors:  Giuseppe Maiolino; Valeria Bisogni; Giacomo Rossitto; Gian Paolo Rossi
Journal:  World J Cardiol       Date:  2015-10-26

Review 4.  Lp-PLA(2) as a marker of cardiovascular diseases.

Authors:  Sabha Bhatti; Abdul Hakeem; Mehmet Cilingiroglu
Journal:  Curr Atheroscler Rep       Date:  2010-03       Impact factor: 5.113

Review 5.  Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literature.

Authors:  Mohammad Madjid; Muzammil Ali; James T Willerson
Journal:  Tex Heart Inst J       Date:  2010

6.  Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community.

Authors:  Yariv Gerber; Shannon M Dunlay; Allan S Jaffe; Joseph P McConnell; Susan A Weston; Jill M Killian; Véronique L Roger
Journal:  Atherosclerosis       Date:  2008-08-07       Impact factor: 5.162

7.  Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study.

Authors:  Emmanouil S Brilakis; Amit Khera; Darren K McGuire; Raphael See; Subhash Banerjee; Sabina A Murphy; James A de Lemos
Journal:  Atherosclerosis       Date:  2007-12-03       Impact factor: 5.162

Review 8.  Role of lipoprotein-associated phospholipase A2 in atherosclerosis.

Authors:  Shahar Lavi; Joerg Herrmann; Ronit Lavi; Joseph P McConnell; Lilach O Lerman; Amir Lerman
Journal:  Curr Atheroscler Rep       Date:  2008-06       Impact factor: 5.113

9.  The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults.

Authors:  Maria Weinkouff Pedersen; Wolfgang Koenig; Jeppe Hagstrup Christensen; Erik Berg Schmidt
Journal:  Eur J Nutr       Date:  2008-11-21       Impact factor: 5.614

Review 10.  Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.